Summary: As pharma companies look more and more to biologics for their next potential blockbusters, they must face the challenges surrounding these products’ scientific complexity and sophisticated development.

This eBook will explore:

• Survey insight on biopharma growth strategies and risk management
• Why low manufacturing costs are critical for biosimilar success
• Current biopharma facility investment trends
• How new formats and formulations will change CMC requirements

Click here to read article.